EUVIMEDEUVIMED entdecken
Crossref

Determining Optimal Patient Selection for High-intensity Focused Ultrasound for Prostate Cancer

Kevin Shee, William A Pace, Andrew W Liu, Janet E Cowan, Vishvak Subramanyam, Cameron Agapito, Samuel L Washington, Matthew R Cooperberg, Peter R Carroll, Katsuto Shinohara, Hao G Nguyen

European Urology Focus · 2025-11 · 11 (6) · 869-875

DOI: 10.1016/j.euf.2025.06.007 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Urology Focus, 2025-11. Verfasst von Kevin Shee und 10 weiteren Autor:innen. Beteiligte Einrichtung: UCSF Department of Urology, UCSF Helen Diller Comprehensive Cancer Center, San Francisco, CA, USA. Electronic address: Kevin.shee@ucsf.edu. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Patient Selection, High-Intensity Focused Ultrasound Ablation, Ultrasound, High-Intensity Focused, Transrectal. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: University of California, San Francisco.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND AND OBJECTIVE: Magnetic resonance imaging (MRI)/ultrasound-guided high-intensity focused ultrasound (HIFU) ablates prostate cancer with promising cancer control and minimal impact on sexual or urinary function. However, recurrence remains a concern. This study identifies factors associated with recurrence and treatment failure to optimize patient selection. METHODS: Men who underwent robotic HIFU (FocalOne) at University of California San Francisco (2021-2023) and had a 1-yr post-HIFU MRI-fusion biopsy were included. The primary outcomes were biopsy-proven in-field and overall recurrence. The secondary outcomes included treatment failure (salvage whole-gland treatment with surgery or radiation, or development of metastases) and changes in urinary/sexual function. Cox proportional hazards and multivariable logistic regression were used for an analysis. KEY FINDINGS AND LIMITATIONS: Among 135 men with a follow-up biopsy at 12 mo, pre-HIFU Gleason grade ≥3 (≥GG3; hazard ratio [HR] 3.11; 95% confidence interval [CI] 1.30-7.47) and a high genomic risk score (HR 2.87; 95% CI 1.18-6.99) were associated with in-field biopsy-proven recurrence. Overall biopsy-proven recurrence was linked to ≥GG3 (HR 2.62; 95% CI 1.03-6.67) and prostate-specific antigen (PSA) >10 versus 2 complications, urethral stricture, or urethra-rectal fistula were recorded. CONCLUSIONS AND CLINICAL IMPLICATIONS: Pre-HIFU ≥GG3 disease, a high genomic risk score, and elevated PSA correlate with local recurrence. These findings emphasize the importance of careful patient selection, as HIFU can effectively control cancer with minimal urinary or sexual side effects in suitable patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsPatient SelectionHigh-Intensity Focused Ultrasound AblationUltrasound, High-Intensity Focused, TransrectalHumansMaleAgedMiddle AgedNeoplasm Recurrence, LocalNeoplasm GradingRetrospective Studies

Stichwörter der Autor:innen

Focal ablative therapyHigh-intensity focused ultrasound ablationProstate cancer

Autor:innen und Institutionen

  • UCSF Department of Urology, UCSF Helen Diller Comprehensive Cancer Center, San Francisco, CA, USA. Electronic address: Kevin.shee@ucsf.edu.
  • UCSF Department of Urology, UCSF Helen Diller Comprehensive Cancer Center, San Francisco, CA, USA.
  • UCSF Department of Biological and Medical Informatics, University of California San Francisco, San Francisco, CA, USA.
  • UCSF Department of Urology, UCSF Helen Diller Comprehensive Cancer Center, San Francisco, CA, USA; UCSF Department of Epidemiology & Biostatistics, University of California San Francisco, San Francisco, CA, USA.
  • UCSF Department of Urology, UCSF Helen Diller Comprehensive Cancer Center, San Francisco, CA, USA. Electronic address: Hao.nguyen@ucsf.edu.

Förderung

  • University of California, San Francisco

Zitieren

APA

Shee, K., Pace, W. A., Liu, A. W., Cowan, J. E., Subramanyam, V., Agapito, C., Washington, S. L., Cooperberg, M. R., Carroll, P. R., Shinohara, K., & Nguyen, H. G. (2025). Determining Optimal Patient Selection for High-intensity Focused Ultrasound for Prostate Cancer. European Urology Focus, 11(6), 869-875. https://doi.org/10.1016/j.euf.2025.06.007

Vancouver

Shee K, Pace WA, Liu AW, Cowan JE, Subramanyam V, Agapito C, et al. Determining Optimal Patient Selection for High-intensity Focused Ultrasound for Prostate Cancer. European Urology Focus. 2025;11(6):869-875. doi:10.1016/j.euf.2025.06.007

BibTeX
@article{Shee2025,
  author = {Shee, Kevin and Pace, William A and Liu, Andrew W and Cowan, Janet E and Subramanyam, Vishvak and Agapito, Cameron and Washington, Samuel L and Cooperberg, Matthew R and Carroll, Peter R and Shinohara, Katsuto and Nguyen, Hao G},
  title = {Determining Optimal Patient Selection for High-intensity Focused Ultrasound for Prostate Cancer},
  journal = {European Urology Focus},
  year = {2025},
  volume = {11},
  number = {6},
  pages = {869--875},
  doi = {10.1016/j.euf.2025.06.007}
}
Kostenlos starten →